TVs to Biologics: Samsung Dives into Biosimilars with $300M Biogen Idec JV BioWorld Online It markets Tysabri (natalizumab) and Avonex (Interferon beta-1a) for multiple sclerosis, and Rituxan (rituximab) for non-Hodgkin lymphoma. Its development pipeline includes products for cancer, multiple sclerosis, hemophilia A and B and other ... |
